Table 3.
Baseline demographic and clinical characteristics stratified by treatment sequence in patients with ulcerative colitis.
| Total (N = 1640)a | ADA to IFX (n = 330) | ADA to VDZ (n = 401) | ADA to UST (n = 33) | IFX to ADA (n = 266) | IFX to VDZ (n = 374) | IFX to UST (n = 21) | VDZ to ADA (n = 64) | VDZ to IFX (n = 119) | VDZ to UST (n = 30) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Demographic | ||||||||||
| Age, y | 43.7 (16.5) | 41.8 (15.8) | 43.7 (15.6) | 40.1 (16.2) | 41.8 (15.2) | 45.2 (18.2) | 40.2 (14.1) | 47.1 (16.1) | 47.2 (18.5) | 47.3 (16.1) |
| Sex | ||||||||||
| Female | 50.5 | 49.1 | 47.9 | 60.6 | 53.0 | 53.2 | 61.9 | 45.3 | 46.2 | 50.0 |
| Male | 49.5 | 50.9 | 52.1 | 39.4 | 47.0 | 46.8 | 38.1 | 54.7 | 53.8 | 50.0 |
| Race/ethnicity | ||||||||||
| Asian | 1.8 | 1.5 | 1.5 | 3.0 | 1.5 | 2.1 | 0.0 | 3.1 | 2.5 | 0.0 |
| Black or African American | 5.2 | 6.4 | 3.0 | 0.0 | 8.3 | 5.1 | 4.8 | 3.1 | 5.0 | 6.7 |
| White or Caucasian | 88.1 | 88.8 | 91.5 | 90.9 | 85.0 | 86.1 | 85.7 | 85.9 | 89.1 | 86.7 |
| Unknown or other | 4.9 | 3.3 | 4.0 | 6.1 | 5.3 | 6.7 | 9.5 | 7.8 | 3.4 | 6.7 |
| Insurance type | ||||||||||
| Commercial | 65.9 | 66.1 | 69.8 | 75.8 | 66.2 | 65.2 | 61.9 | 56.3 | 53.8 | 76.7 |
| Medicaid | 6.8 | 8.5 | 4.5 | 3.0 | 7.1 | 9.4 | 4.8 | 3.1 | 6.7 | 0.0 |
| Medicare | 7.9 | 7.9 | 5.5 | 0.0 | 5.3 | 10.4 | 4.8 | 9.4 | 16.0 | 6.7 |
| Commercial/Medicaid | 2.7 | 3.0 | 2.0 | 0.0 | 3.4 | 2.1 | 14.3 | 4.7 | 2.5 | 0.0 |
| Commercial/Medicare | 3.8 | 2.7 | 4.5 | 3.0 | 2.6 | 4.3 | 4.8 | 3.1 | 6.7 | 3.3 |
| Medicaid/Medicare | 0.7 | 0.3 | 1.0 | 0.0 | 0.8 | 0.8 | 0.0 | 0.0 | 1.7 | 0.0 |
| Commercial/Medicaid/ Medicare |
0.1 | 0.0 | 0.0 | 0.0 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Uninsured | 1.4 | 0.9 | 0.5 | 9.1 | 3.8 | 0.5 | 0.0 | 1.6 | 0.8 | 3.3 |
| Missing, unknown, or other | 10.6 | 10.6 | 12.2 | 9.1 | 10.5 | 7.0 | 9.5 | 21.9 | 11.8 | 10.0 |
| Clinical characteristic | ||||||||||
| Conditions in the pre–index periodb | ||||||||||
| Cardiovascular disease | 25.9 | 22.1 | 22.4 | 24.2 | 28.2 | 31.8 | 23.8 | 21.9 | 27.7 | 23.3 |
| Mental disorder | 19.2 | 16.1 | 19.2 | 33.3 | 24.1 | 20.9 | 9.5 | 18.8 | 14.3 | 3.3 |
| Chronic pulmonary disease | 12.5 | 10.9 | 12.0 | 6.1 | 15.4 | 13.1 | 9.5 | 12.5 | 15.1 | 0.0 |
| Diabetes mellitus | 7.3 | 7.3 | 6.5 | 3.0 | 5.6 | 9.1 | 9.5 | 4.7 | 10.1 | 10.0 |
| Liver disease | 6.4 | 8.2 | 5.2 | 3.0 | 6.4 | 7.0 | 0.0 | 4.7 | 6.7 | 6.7 |
| CCI score | 0.5 (1.0) | 0.4 (0.9) | 0.5 (1.0) | 0.2 (0.5) | 0.5 (1.0) | 0.5 (1.0) | 0.7 (1.0) | 0.8 (1.2) | 0.8 (1.3) | 0.6 (1.1) |
| Body mass index, kg/m2 | 27.3 (6.3) | 27.8 (6.5) | 27.7 (6.4) | 27.4 (6.2) | 27.2 (6.8) | 26.9 (6.3) | 25.7 (5.1) | 26.1 (5.3) | 27.4 (5.6) | 26.2 (5.9) |
| Smoking | 16.0 | 18.5 | 12.5 | 18.2 | 17.7 | 18.5 | 14.3 | 10.9 | 14.3 | 6.7 |
| Disease extent | ||||||||||
| Pancolitis | 45.2 | 47.3 | 40.9 | 45.5 | 44.7 | 47.1 | 47.6 | 45.3 | 53.8 | 26.7 |
| Left-sided disease | 9.8 | 8.8 | 12.5 | 0.0 | 11.7 | 9.1 | 4.8 | 12.5 | 5.9 | 3.3 |
| Proctosigmoiditis | 7.9 | 8.5 | 12.0 | 9.1 | 2.6 | 5.6 | 4.8 | 9.4 | 8.4 | 20.0 |
| Proctitis, other, and unspecified | 37.0 | 35.5 | 34.7 | 45.5 | 41.0 | 38.2 | 42.9 | 32.8 | 31.9 | 50.0 |
| Duration of conventional therapy | ||||||||||
| 0 d | 13.0 | 8.8 | 11.7 | 21.2 | 10.5 | 15.2 | 23.8 | 7.8 | 20.2 | 36.7 |
| 1-30 d | 12.1 | 11.5 | 9.5 | 12.1 | 12.4 | 16.3 | 4.8 | 3.1 | 14.3 | 13.3 |
| 31-60 d | 12.0 | 11.2 | 12.7 | 9.1 | 13.5 | 11.8 | 19.1 | 15.6 | 8.4 | 3.3 |
| 61-90 d | 9.9 | 11.2 | 9.2 | 9.1 | 7.9 | 11.8 | 4.8 | 7.8 | 9.2 | 6.7 |
| ≥91 d | 53.1 | 57.3 | 56.9 | 48.5 | 55.6 | 44.9 | 47.6 | 65.6 | 47.9 | 40.0 |
Values are mean (SD) or %.
Abbreviations: ADA, adalimumab; CCI, Charlson Comorbidity Index; IFX, infliximab; UST, ustekinumab; VDZ, vedolizumab.
aIncluding 2 patients with ulcerative colitis who received UST as a first-line biologic.
bThe 5 most prevalent conditions in the total ulcerative colitis cohort.